Last reviewed · How we verify
Gleevec, RAD001, and Hydroxyurea — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Gleevec, RAD001, and Hydroxyurea (Gleevec, RAD001, and Hydroxyurea) — Annick Desjardins.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Gleevec, RAD001, and Hydroxyurea TARGET | Gleevec, RAD001, and Hydroxyurea | Annick Desjardins | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Gleevec, RAD001, and Hydroxyurea CI watch — RSS
- Gleevec, RAD001, and Hydroxyurea CI watch — Atom
- Gleevec, RAD001, and Hydroxyurea CI watch — JSON
- Gleevec, RAD001, and Hydroxyurea alone — RSS
Cite this brief
Drug Landscape (2026). Gleevec, RAD001, and Hydroxyurea — Competitive Intelligence Brief. https://druglandscape.com/ci/gleevec-rad001-and-hydroxyurea. Accessed 2026-05-21.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab